×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RLMD – relmada therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/9
07:30 am
rlmd
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Low
Report
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
12/6
05:31 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
12/6
05:31 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.
Low
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.
12/5
08:02 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.
High
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.
12/5
08:01 am
rlmd
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.
High
Report
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.
11/25
05:34 pm
rlmd
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsight [Yahoo! Finance]
Low
Report
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsight [Yahoo! Finance]
11/21
01:34 pm
rlmd
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
11/19
09:14 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:10 pm
rlmd
relmada therapeutics, inc.
MISS
Report
3.5%
relmada therapeutics, inc.
8/7/2024
04:05 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-29.0%
relmada therapeutics, inc.
5/8/2024
04:05 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-0.8%
relmada therapeutics, inc.
3/19/2024
04:15 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-17.4%
relmada therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/9
07:50 am
rlmd
Form 8-K RELMADA THERAPEUTICS, For: Dec 09
Low
Report
Form 8-K RELMADA THERAPEUTICS, For: Dec 09
11/14
09:41 am
rlmd
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
Neutral
Report
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
11/7
04:07 pm
rlmd
Form 10-Q RELMADA THERAPEUTICS, For: Sep 30
Medium
Report
Form 10-Q RELMADA THERAPEUTICS, For: Sep 30
10/23
04:27 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: Oct 22 Filed by: CASAMENTO CHARLES J
Low
Report
Form 4 RELMADA THERAPEUTICS, For: Oct 22 Filed by: CASAMENTO CHARLES J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
TOP News Decliners
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: